Skip to main content

Table 2 Baseline characteristics of patients with pegylated interferon α2a

From: Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy

Characteristics

Combined responses at 48 weeks

 

Yes (n=22)

No (n=21)

p value

Age, yrs

32.7±8.7

32.2±7.1

NS

Men, n(%)

13(59.1%)

17(81.0%)

NS

ALT level, n(%)

   

≥3×ULN

14(63.6%)

8(38.1%)

NS

ALT level,IU/L

209±137

171±113

NS

HBV DNA ≥1×107 copies/mL,%

12(54.5%)

17(81.0%)

NS

HBV DNA(log10 copies/mL)

7.1±0.7

7.5±1.0

NS

HBsAg ≥2×104 IU/ml,%

5(22.7%)

12(57.1%)

0.031

HBsAg(log10 IU/mL)

3.8±0.8

4.2±0.6

0.070

HBV genotype, n (%)

   

B

15(68.2%)

15(71.4%)

NS

C

7(31.8%)

5(23.8%)

 

B and C

0(0)

1( 4.8%)

 
  1. ALT: alanine aminotransferase; ULN: upper limit of normal; combined responses at 48 weeks: both HBV DNA< 1000 copies/ml and HBeAg loss at the end of 48 weeks treatment; NS: no significant difference.